Special Issue

Advances in Robotic Neurorehabilitation

Message from the Guest Editor

This Special Issue aims to bring together a diverse contributions, ranging from fundamental research to clinical applications, with a focus on how robotic technologies are augmenting and optimizing neurorehabilitation interventions. These devices. ranging from exoskeletons to wearable sensors and VR tools, are providing targeted and personalized interventions for individuals recovering from different neurological impairments. Additionally, the aim of this Special Issue is to provide an overview of the possibilities and advancements in different aspects in the field of robotic neurorehabilitation, including the preclinical and clinical testing of novel machines and tools for robotic neurorehabilitation. Authors are also encouraged to submit their technical notes, clinical outcome studies, patient satisfaction studies, and systematic reviews and meta-analyses for various robotic interventions. Case series and case reports of high quality will be considered for publication.

Guest Editor

Dr. Ivo Dumic-Cule

- Clinical Department of Diagnostic and Interventional Radiology, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia
- 2. Department of Nursing, University North, 104 Brigade 3, 42000 Varazdin, Croatia

Deadline for manuscript submissions

30 June 2025



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/195816

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

